Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 604-047-3 | CAS number: 137863-20-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Dec 1996 - Aug 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian bone marrow chromosome aberration test
Test material
- Reference substance name:
- Tetrazolyl-valinesteramid (3-methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid benzyl ester)
- EC Number:
- 604-047-3
- Cas Number:
- 137863-20-8
- Molecular formula:
- C31 H35 N5 O3
- IUPAC Name:
- Tetrazolyl-valinesteramid (3-methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid benzyl ester)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Tif: RAif (SPF) rats
- Details on species / strain selection:
- Young adult male and female rats (Tif: RAif (SPF)) were reared under SPF conditions by Novartis Pharma AG.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Young adult male and female rats (Tif: RAif (SPF)) were reared under SPF conditions by Novartis Pharma AG. The air-conditioned animal rooms were maintained at a temperature of 20.0 - 21.0°C and a relative humidity of 24 - 46%. The room was illuminated for 12 hours daily. The rats were fed a standard diet of NAFAG No. 890 and tap water ad libitum. They were kept on location for at least five days prior to being used in the study. Shortly before use the health status of the animals was checked by the laboratory personnel according to veterinary/scientific standards. The animals were housed 5/cage (micronucleus test), 3/cage (reserve animals) or individually (tolerability test) and marked with color pens. They were distributed to the different treatment and control groups by random selection with the aid of a computer generated random list.
Prior to application of the test substance or the control substances, the weight of the animals was determined. The age range at the time of application was 7 to 8 weeks.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- Arachis oil
- Details on exposure:
- The test substance, the negative and positive controls were dosed at a volume of 10 ml/kg body weight by gavage.
Oral by stomach tube, 10 ml/kg body weight - Duration of treatment / exposure:
- The test substance was administered once by gavage to groups of 5 male and 5 female Tif: RAif (SPF) rats at three different doses. Additional groups of animals were treated with the vehicle alone or with the positive control cyclophosphamide ( 40 mg/kg). From the high dose group and from the negative control group animals were sacrificed 16, 24 and 48 hours thereafter. From the intermediate and the low dose group and from the positive control group animals were sacrificed
24 hours after application. Dose-finding was carried out in a preceding tolerability test. - Frequency of treatment:
- The following numbers of animals/sex/dose were treated and analyzed:
Preparation of bone marrow High dose (HD) Intermediate dose (ID) Low dose (LD) Positive control Negative control
after treatment 1250mg/kg 625 mg/kg 312.5 mg/kg (CPA) (vehicle)
16 hours 5m+5f 5m+5f
24 hours 5m+5f 5m+5f 5m+5f 5m+5f 5m+5f
48 hours 5m+5f 5m+5f
Reserve* 3m+3f
*) BM of reserve animals prepared only in case of premature death in the HD group
Doses / concentrationsopen allclose all
- Dose / conc.:
- 2 000 mg/kg bw/day
- Remarks:
- tolerability test
- Dose / conc.:
- 1 250 mg/kg bw/day
- Dose / conc.:
- 312.5 mg/kg bw/day
- Dose / conc.:
- 625 mg/kg bw/day
- No. of animals per sex per dose:
- The following numbers of animals/sex/dose were treated and analyzed:
Preparation of bone marrow High dose (HD) Intermediate dose (ID) Low dose (LD) Positive control Negative control
after treatment 1250mg/kg 625 mg/kg 312.5 mg/kg (CPA) (vehicle)
16 hours 5m+5f 5m+5f
24 hours 5m+5f 5m+5f 5m+5f 5m+5f 5m+5f
48 hours 5m+5f 5m+5f
Reserve* 3m+3f
*) BM of reserve animals prepared only in case of premature death in the HD group - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- the positive control cyclophosphamide ( 40 mg/kg)
Examinations
- Evaluation criteria:
- The results of the experiments were evaluated with respect to the mean number of PCEs with micronuclei.
The groups compared differed by treatment, sampling time and sex of the animals. The data from females and males were pooled for evaluation. In case of significant sex differences data have to be evaluated for each sex separately in addition.
Assay acceptance criteria
1. The result of the experiment should not be influenced by a significant technical error or a recognized artifact.
2. The high dose of the test substance applied should be the maximum tolerated dose causing no death in a group of four animals in the range finding-test. In the absence of lethality in the tolerability test, the high dose should be up to a maximum of 2000 mg/kg body weight or the
highest applicable dose due to the limited solubility of the test substance.
3. The quality of the slides must allow a clear differentiation between PCEs and NCEs.
4. The mean number of micronucleated PCEs in the negative control groups should not exceed the value of 0.20%.
5. The positive control should fulfill the criteria for an active substance. - Statistics:
- The significance of differences was assessed by the Chi-Squared-Contingency-Test (df=1, p<0.05).
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
Any other information on results incl. tables
The dose finding experiment with PBS 859 DS showed that treatment with 2000 mg/kg led to severe signs of toxicity, such as ventral recumbency, ataxia, reduced locomotor activity, dyspnea, hunched posture, and loss in body weight and led to the death of an animal. At 1250 mg/kg, similar, but less severe signs was observed. This dose was confirmed by treating a second pair of rats. Based on these results, doses of 312.5, 625 and 1250 mg/kg were chosen for the micronucleus test.
In the micronucleus test, the percentage of PCEs was not decreased in any of the dose groups. No signs of bone marrow toxicity were observed. At the 16 hours sampling time in the group treated with 1250 mg/kg of the test substance the mean percentage of micronucleated PCEs was 0.13 compared to a negative control value of 0.11. At the 24 hours sampling time in the groups treated with the test substance the mean percentage of micronucleated PCEs was 0.16 (1250 mg/kg), 0.13 (625 mg/kg) and 0.18 (312.5 mg/kg) respectively. The respective negative control value for this group was 0.15%. At the 48 hours sampling time in the group treated with 1250 mg/kg of the test substance the mean percentage of micronucleated PCEs was 0.15 compared to a negative control value of 0.12. In the positive control (24 hours) the mean percentage of micronucleated PCEs ( 1.19) was significantly increased.
Applicant's summary and conclusion
- Conclusions:
- In all dosage groups assessed at the different periods post treatment, no statistically significant increase in the number of micronucleated polychromatic erythrocytes was observed when compared with the respective negative control group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.